{"id":616688,"date":"2024-06-18T06:59:52","date_gmt":"2024-06-18T10:59:52","guid":{"rendered":"https:\/\/platohealth.ai\/using-diabetes-drug-metformin-around-pregnancy-wont-raise-birth-defect-risk-drugs-com-mednews\/"},"modified":"2024-06-18T10:52:47","modified_gmt":"2024-06-18T14:52:47","slug":"using-diabetes-drug-metformin-around-pregnancy-wont-raise-birth-defect-risk-drugs-com-mednews","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/using-diabetes-drug-metformin-around-pregnancy-wont-raise-birth-defect-risk-drugs-com-mednews\/","title":{"rendered":"Using Diabetes Drug Metformin Around Pregnancy Won’t Raise Birth Defect Risk – Drugs.com MedNews","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"

<\/p>\n

Medically reviewed<\/a> by Drugs.com.<\/span><\/p>\n

By Robin Foster HealthDay Reporter<\/p>\n

TUESDAY, June 18, 2024 — Two new studies offer reassurance that using the diabetes drug metformin before and during pregnancy is not linked to birth defects.<\/p>\n

The latest findings, which apply to men planning to conceive with their partners or women in early pregnancy, contradict a 2022 study<\/a> that found metformin use by men in the three months before they conceived a baby was associated with a 40% increased risk of birth defects in their children. <\/p>\n

\u201cConventionally and traditionally, the mother has been the focus when it comes to pregnancy and when it comes to fetal health and the health of the newborn. What we are increasingly finding is that the father is also important,\u201d Dr. Ran Rotem<\/a>, who authored the new study<\/a> on the paternal use of metformin and birth defects, told CNN<\/em>.<\/p>\n

\u201cWe know that diabetes itself is not good when it is in the mother, and we are finding evidence that it\u2019s also tricky for the fathers,\u201d Rotem noted. \u201cIf you can manage diabetes with just changing your lifestyle — doing more exercise, watching your diet — that\u2019s probably good, and that\u2019s helpful anyways. But if you have to be medicated, it seems like metformin is a safe choice for both.\u201d<\/p>\n

The raised risk of birth defects seen in earlier research <\/strong>could have been associated with diabetes itself or with related illnesses, instead of the medication, noted Rotem, a researcher at the Harvard T.H. Chan School of Public Health in Boston.<\/p>\n

\u201cWhen we think about a medication, we also have to think about the underlying conditions in which the medication is usually prescribed,\u201d Rotem said. \u201cWe know that diabetes itself is tricky when it comes to both fertility and potential complications in pregnancy and in newborns.\u201d<\/p>\n

In Rotem’s study, his team analyzed data from medical records on nearly 400,000 babies born in Israel between 1999 and 2020. They compared that with information on the babies\u2019 fathers, such as their ages, lab test results and medication records.<\/p>\n

His team found the rate of major birth defects was 4.7% in children of fathers not exposed to diabetes medications in the months leading up to conception, compared with 6.2% in children of fathers exposed to metformin before conceiving.<\/p>\n

But when the researchers also weighed fathers\u2019 other underlying health conditions and whether the mother also had diabetes or related co-morbidities, they found no increased risk of major birth defects in children exposed to paternal metformin.<\/p>\n

The data did show that the risk of a birth defect was higher when the father used other medications along with metformin.<\/p>\n

\u201cWhen we examined specific treatment regimens, modestly elevated excess risks were still observed, specifically among children of fathers who used metformin in tandem with some other diabetes medication,\u201d Rotem said.<\/p>\n

\u201cBut we also observed that fathers who took multiple medications had more poorly controlled diabetes,\u201d he added. \u201cThis again indicates that the modestly elevated risk seen for diabetes polytherapies was likely not caused by the medications themselves, but rather by the worse cardio-metabolic health profile of the fathers.\u201d<\/p>\n

The second study, published Tuesday in the Annals of Internal Medicine<\/a><\/em> alongside Rotem’s research, reported similar findings for women. Those who continued using metformin while adding insulin as a treatment in their first trimester of pregnancy showed little to no increased risk of giving birth to a baby with birth defects.<\/p>\n

Those researchers, also from Harvard T.H. Chan School of Public Health, studied Medicaid data on more than 12,000 women with type 2 diabetes and their pregnancies.<\/p>\n

The estimated risk for giving birth to a baby with birth defects was about 6% when the mother received insulin plus metformin, versus 8% when the mother received insulin alone.<\/p>\n

\u201cWe were not surprised by our findings. Although metformin may cross the placenta, potentially affecting the fetus, metformin can help with blood sugar control which may lower the risk of birth defects,\u201d study author Dr. Yu-Han Chiu<\/a>, a researcher at the Harvard T.H. Chan School of Public Health and Penn State College of Medicine, told CNN<\/em>.<\/p>\n

\u201cPoor blood sugar control is a risk factor for birth defects. Insulin in combination with metformin may result in better blood sugar control than using insulin alone. This may explain why we observed a slightly lower risk of live birth with congenital malformations when comparing with using insulin alone,\u201d Chiu said. <\/p>\n

The new studies begin to clarify the risks of metformin use around pregnancy by both parents, Dr. Sarah Martins da Silva<\/a>, of the University of Dundee in Scotland, wrote in an editorial<\/a> published with the studies.<\/p>\n

\u201cNonetheless, these recent analyses suggest that metformin is a safe and effective treatment option for [type 2 diabetes] for men and women trying to conceive as well as managing hyperglycemia [high blood sugar] in pregnant women in the first trimester, and it may be time to reconsider current prenatal care guidelines that advocate switching to insulin therapy,\u201d she added.<\/p>\n

\n

Sources<\/h2>\n